10:58 AM EDT, 04/04/2024 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) unit Teva Pharmaceuticals International and mAbxience said Thursday that they entered into a licensing agreement for a biosimilar candidate for the treatment of multiple oncology indications in global markets, including Europe and the US.

Financial details of the deal weren't disclosed.

mAbxience will use its facilities and its expertise in biosimilar development to produce the biosimilar product, while Teva will lead the regulatory processes and commercialization, the companies said.

Price: 14.03, Change: -0.09, Percent Change: -0.64